ASCO 2022 | How will adagrasib fit into the treatment landscape of KRASG12-mutant NSCLC?

So we hope adagrasib is… It’s not yet approved in the United States. We hope that it’ll be approved by the end of the year, as well as in the European Union as well. If you look side by side, and of course we’re not supposed to do cross-trial comparisons, it appears to be, overall, relatively similar within confidence interval errors to sotorasib. So it’ll provide patients another choice. We’re hoping to get some updated data on, as we change from capsule to tablet form, which we think will be better tolerated, as well as starting with a lower dose as well. So we think there’ll be some more data, but as I said, right now, it appears to be very similar to sotorasib, which will give physicians some choice. And also, obviously, validates that KRAS G12C is a druggable mutation, which is huge.

We also have some hints of CNS data. As I said, that’ll be updated early next week. And I think that’s a really important thing, because patients often have brain metastases. They progress in the brain, and this will be the first presentation of activity and brain metastases of any drug for KRAS G12C, so that’s super exciting as well.